Riskpilot← Back to searchSign inGet full accessOribac AB
ABIn liquidationOrg 5567088678Other research and experimental development on natural sciences and engineering · NACE 7219Est. 20060 employees
Revenue 2022
SEK 0
EBITDA margin
—
-38% vs 2021
Equity ratio
100.0%
Financial strength
Net profit 2022
SEK -18K
-38% vs 2021
| Revenue | SEK 0 | — |
| EBITDA | SEK -18K | -38% |
| Net profit | SEK -18K | -38% |
| Total assets | SEK 10K | +25% |
| Equity | SEK 10K | +110% |
| Employees | 0 | — |
Legal name
Oribac AB
Org number
5567088678
Legal form
Aktiebolag
NACE code
7219 · Other research and experimental development on natural sciences and engineering
Founded
18 augusti 2006
Share capital
SEK 107 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Bolaget ska bedriva utveckling och marknadsföring av probiotika-baserade produkter främst inom det medicinska området samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenue | 0 | 8 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −40 | −1 139 | −17 | −13 | −18 |
| Depreciation & amort. | −0 | −0 | −93 | −0 | −0 |
| EBIT | −40 | −1 139 | −110 | −13 | −18 |
| Net financials | — | — | 850 | — | — |
| Profit before tax | −40 | −1 139 | 740 | −13 | −18 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −40 | −1 139 | 740 | −13 | −18 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Total assets | 1 232 | 104 | 3 | 8 | 10 |
| Equity | 312 | −827 | −87 | −100 | 10 |
| Long-term debt | 850 | 850 | 0 | 0 | 0 |
| Short-term debt | 70 | 81 | 89 | 108 | 0 |
| Total debt | 920 | 931 | 89 | 108 | — |
EBITDA margin
-1800000.0%
This company
15.8%
Market median
-11392505% vs market
20182022
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20182022
Return on equity
-180.0%
This company
18.4%
Market median
-1078% vs market
20182022
Net profit margin
-1800000.0%
This company
8.1%
Market median
-22222322% vs market
20182022
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20182022
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20182022
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
BJ Audit | Audit | 2022 |
AC Liquidator | Liquidator | 2022 |
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
| Deputy Board Member | 2022 – 2022 | |
| Chairman | 2022 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Oribac AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Björn Jonas Jonasson | Audit | 0 companies |
| Annica C M Torstensson Almståhl | Liquidator | 0 companies |
| Jan Anders Ragnar Henriksson | Deputy Board Member | 0 companies |
| Maude Birgitta Wikström | Chairman | 0 companies |